Interleukin‐1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset

It was hypothesized that IL‐1 antagonism would preserve β‐cell function in new onset Type 1 diabetes (T1D). However, the Anti‐Interleukin‐1 in Diabetes Action (AIDA) and TrialNet Canakinumab (TN‐14) trials failed to show efficacy of IL‐1 receptor antagonist (IL‐1Ra) or canakinumab, as measured by st...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of immunology 2016-04, Vol.46 (4), p.1030-1046
Hauptverfasser:	Cabrera, Susanne M., Wang, Xujing, Chen, Yi‐Guang, Jia, Shuang, Kaldunski, Mary L., Greenbaum, Carla J., Mandrup‐Poulsen, Thomas, Hessner, Martin J.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Anakinra Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Beta cells Canakinumab Cells, Cultured Clinical trials Cytokines Diabetes Diabetes mellitus Diabetes Mellitus, Type 1 - drug therapy Diabetes Mellitus, Type 1 - immunology Humans Immunomodulation Immunotherapy - methods Inflammation Inflammation - immunology Inhibition Insulin-Secreting Cells - physiology Interleukin 1 Interleukin 1 receptor antagonist Interleukin 1 Receptor Antagonist Protein - therapeutic use Interleukin-1alpha - immunology Interleukin-1beta - antagonists & inhibitors Interleukin-1beta - immunology Male Neutralization Transcription Transcriptional signatures Type 1 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!